CORT Quote, Financials, Valuation and Earnings

Collegium Pharmaceutical has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 1.36%. Corcept Therapeutics's return on equity of 21.3% beat Collegium Pharmaceutical's return on equity of 19.31%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 89.13%. On the other hand Collegium Pharmaceutical has an analysts' consensus of $41.25 which suggests that it could grow by 27.87%. Given that Corcept Therapeutics has higher upside potential than Collegium Pharmaceutical, analysts believe Corcept Therapeutics is more attractive than Collegium Pharmaceutical.

Corcept Therapeutics has a beta of 0.154, which suggesting that the stock is 84.623% less volatile than S&P 500. In comparison Collegium Pharmaceutical has a beta of 0.639, suggesting its less volatile than the S&P 500 by 36.077%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Collegium Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Collegium Pharmaceutical pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Collegium Pharmaceutical quarterly revenues of $177.8M. Corcept Therapeutics's net income of $20.5M is higher than Collegium Pharmaceutical's net income of $2.4M. Notably, Corcept Therapeutics's price-to-earnings ratio is 63.02x while Collegium Pharmaceutical's PE ratio is 26.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.37x versus 1.87x for Collegium Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 13.07% compared to Corcept Therapeutics's net margin of -49.65%. Corcept Therapeutics's return on equity of 21.3% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 89.13%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that Corcept Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than NovaBay Pharmaceuticals.

Corcept Therapeutics has a beta of 0.154, which suggesting that the stock is 84.623% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Corcept Therapeutics's net income of $20.5M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Corcept Therapeutics's price-to-earnings ratio is 63.02x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.37x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 21.63%. Corcept Therapeutics's return on equity of 21.3% beat Pfizer's return on equity of 8.72%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 89.13%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.92%. Given that Corcept Therapeutics has higher upside potential than Pfizer, analysts believe Corcept Therapeutics is more attractive than Pfizer.

Corcept Therapeutics has a beta of 0.154, which suggesting that the stock is 84.623% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.92% to investors and pays a quarterly dividend of $0.43 per share. Corcept Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than Pfizer quarterly revenues of $13.7B. Corcept Therapeutics's net income of $20.5M is lower than Pfizer's net income of $3B. Notably, Corcept Therapeutics's price-to-earnings ratio is 63.02x while Pfizer's PE ratio is 17.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.37x versus 2.24x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of 13.07% compared to Corcept Therapeutics's net margin of 40.56%. Corcept Therapeutics's return on equity of 21.3% beat United Therapeutics's return on equity of 19.92%.

Corcept Therapeutics has a consensus price target of $138.25, signalling upside risk potential of 89.13%. On the other hand United Therapeutics has an analysts' consensus of $377.01 which suggests that it could grow by 26.8%. Given that Corcept Therapeutics has higher upside potential than United Therapeutics, analysts believe Corcept Therapeutics is more attractive than United Therapeutics.

Corcept Therapeutics has a beta of 0.154, which suggesting that the stock is 84.623% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.629%.

Corcept Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Corcept Therapeutics quarterly revenues are $157.2M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Corcept Therapeutics's net income of $20.5M is lower than United Therapeutics's net income of $322.2M. Notably, Corcept Therapeutics's price-to-earnings ratio is 63.02x while United Therapeutics's PE ratio is 11.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics is 12.37x versus 4.79x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.